IN2014CN04251A - - Google Patents
Download PDFInfo
- Publication number
- IN2014CN04251A IN2014CN04251A IN4251CHN2014A IN2014CN04251A IN 2014CN04251 A IN2014CN04251 A IN 2014CN04251A IN 4251CHN2014 A IN4251CHN2014 A IN 4251CHN2014A IN 2014CN04251 A IN2014CN04251 A IN 2014CN04251A
- Authority
- IN
- India
- Prior art keywords
- provides
- present
- compound
- carbohydrate polymer
- immunomodulatory
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000002519 immonomodulatory effect Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 229920001282 polysaccharide Polymers 0.000 abstract 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 abstract 1
- 238000001415 gene therapy Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000002255 vaccination Methods 0.000 abstract 1
- VDCRFBBZFHHYGT-IOSLPCCCSA-N C=CCN(C1=C(N2[C@@H]([C@@H]3O)O[C@H](CO)[C@H]3O)N=C(N)NC1=O)C2=O Chemical compound C=CCN(C1=C(N2[C@@H]([C@@H]3O)O[C@H](CO)[C@H]3O)N=C(N)NC1=O)C2=O VDCRFBBZFHHYGT-IOSLPCCCSA-N 0.000 description 1
- 0 CC(C)[C@@](C(N[C@@](CCCCN)C(Nc1ccc(COC(N(C)CCN(C)C(OC[C@]([C@@]([C@]2O)O)O[C@]2N(C(N=C(N)NC2=O)=C2N2CC=C)C2=O)=O)=O)cc1)=O)=O)NC(COCC*OC*OCC(NN)=O)=O Chemical compound CC(C)[C@@](C(N[C@@](CCCCN)C(Nc1ccc(COC(N(C)CCN(C)C(OC[C@]([C@@]([C@]2O)O)O[C@]2N(C(N=C(N)NC2=O)=C2N2CC=C)C2=O)=O)=O)cc1)=O)=O)NC(COCC*OC*OCC(NN)=O)=O 0.000 description 1
- VAOQALAANCUSFZ-NVQRDWNXSA-N CC1(C)O[C@H]2[C@H](N(C(N=C(N)NC3=O)=C3N3CC=C)C3=O)O[C@H](COC(Oc(cc3)ccc3[N+]([O-])=O)=O)[C@H]2O1 Chemical compound CC1(C)O[C@H]2[C@H](N(C(N=C(N)NC3=O)=C3N3CC=C)C3=O)O[C@H](COC(Oc(cc3)ccc3[N+]([O-])=O)=O)[C@H]2O1 VAOQALAANCUSFZ-NVQRDWNXSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/90—Polysaccharides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Materials Engineering (AREA)
- Transplantation (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2011904656A AU2011904656A0 (en) | 2011-11-09 | Immunomodulatory conjugates | |
PCT/AU2012/001387 WO2013067597A1 (fr) | 2011-11-09 | 2012-11-09 | Conjugués immunomodulateurs |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014CN04251A true IN2014CN04251A (fr) | 2015-07-17 |
Family
ID=48288385
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN4251CHN2014 IN2014CN04251A (fr) | 2011-11-09 | 2012-11-09 |
Country Status (7)
Country | Link |
---|---|
US (1) | US10344261B2 (fr) |
EP (1) | EP2776070A4 (fr) |
JP (1) | JP2014532799A (fr) |
CN (1) | CN104661683A (fr) |
AU (1) | AU2012334825B2 (fr) |
IN (1) | IN2014CN04251A (fr) |
WO (1) | WO2013067597A1 (fr) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2719250C (fr) | 2008-03-28 | 2020-04-07 | Kevin E. Healy | Conjugues polypeptide-polymere et procedes d'utilisation de ceux-ci |
EP3092255A4 (fr) | 2014-01-10 | 2017-09-20 | Birdie Biopharmaceuticals Inc. | Composés et compositions pour le traitement de tumeurs exprimant egfr |
BR112016017261B1 (pt) | 2014-04-22 | 2022-04-19 | F. Hoffmann-La Roche Ag | Composto, composição farmacêutica, uso de um composto e processo para a fabricação de um composto |
US10278984B2 (en) | 2014-05-02 | 2019-05-07 | Nitor Therapeutics | Guanosine as an immune potentiator mediated through toll receptors |
JP6760919B2 (ja) | 2014-07-09 | 2020-09-23 | バーディー バイオファーマシューティカルズ インコーポレイテッド | 腫瘍を治療するための抗pd−l1組み合わせ |
CN112587672A (zh) * | 2014-09-01 | 2021-04-02 | 博笛生物科技有限公司 | 用于***的抗-pd-l1结合物 |
CN115501172A (zh) * | 2014-11-21 | 2022-12-23 | 丹麦技术大学 | 用于局部药物释放的凝胶制剂 |
SI3265458T1 (sl) | 2015-03-06 | 2019-03-29 | F. Hoffmann-La Roche Ag | Benzazepin dikarboksamidne spojine |
CN104804985B (zh) * | 2015-05-27 | 2016-09-07 | 青岛橡胶谷知识产权有限公司 | 过盛气体收集装置 |
ES2925248T3 (es) | 2015-12-09 | 2022-10-14 | Univ California | Métodos para tratar una enfermedad o un trastorno oculares |
CN106943598A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技(北京)有限公司 | 用于***的抗-her2组合 |
CN106943597A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技(北京)有限公司 | 用于***的抗-egfr组合 |
CN106943596A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技(北京)有限公司 | 用于***的抗-cd20组合 |
EP3464274B1 (fr) | 2016-05-23 | 2020-05-27 | H. Hoffnabb-La Roche Ag | Composés de benzazépine dicarboxamide à fonction amide secondaire |
WO2017202704A1 (fr) | 2016-05-23 | 2017-11-30 | F. Hoffmann-La Roche Ag | Composés de benzazépine dicarboxamide à fonction amide tertiaire |
EP3468963B1 (fr) | 2016-06-12 | 2021-10-27 | F. Hoffmann-La Roche AG | Composes carboxamide de dihydropyrimidinyl benzazepine |
WO2018009916A1 (fr) | 2016-07-07 | 2018-01-11 | The Board Of Trustees Of The Leland Stanford Junior University | Conjugués d'adjuvant d'anticorps |
WO2018069375A1 (fr) | 2016-10-11 | 2018-04-19 | Synthon Biopharmaceuticals B.V. | Lieurs auto-immolables non linéaires et conjugués de ceux-ci |
CN108794467A (zh) | 2017-04-27 | 2018-11-13 | 博笛生物科技有限公司 | 2-氨基-喹啉衍生物 |
WO2018232725A1 (fr) | 2017-06-23 | 2018-12-27 | Birdie Biopharmaceuticals, Inc. | Compositions pharmaceutiques |
JP2020526482A (ja) * | 2017-06-28 | 2020-08-31 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | デクチン−2刺激及び癌免疫療法のための方法及び組成物 |
CN108129337B (zh) * | 2018-01-09 | 2020-10-16 | 苏州亚科科技股份有限公司 | 一种三羟烷基氨基甲烷的制备方法 |
KR20210010879A (ko) * | 2018-05-09 | 2021-01-28 | 더 유니버서티 오브 시카고 | 면역 관용 관여 조성물 및 방법 |
BR112020023866A2 (pt) | 2018-05-25 | 2021-04-06 | Primmune Therapeutics, Inc. | Agonistas de tlr7 |
EP3849665A1 (fr) * | 2018-09-12 | 2021-07-21 | Silverback Therapeutics, Inc. | Conjugués d'anticorps d'agonistes de récepteurs de type toll |
US20220143012A1 (en) * | 2019-03-15 | 2022-05-12 | Bolt Biotherapeutics, Inc. | Macromolecule-Supported TLR Agonists |
WO2020190725A1 (fr) | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Immunoconjugués ciblant le her2 |
CR20220282A (es) | 2019-11-26 | 2022-11-28 | Primmune Therapeutics Inc | Agonistas del tlr7 |
KR20230019101A (ko) | 2020-04-29 | 2023-02-07 | 상하이 린진 바이오파마 씨오., 엘티디. | 벤조티아졸릴 비아릴 화합물, 제조 방법 및 용도 |
US20230181743A1 (en) * | 2020-05-21 | 2023-06-15 | Ohio State Innovation Foundation | Functional lipid derivatives and uses thereof |
WO2023229891A1 (fr) * | 2022-05-25 | 2023-11-30 | Ayuvis Research, Inc. | Nouvelles petites molécules immunomodulatrices |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5554386A (en) * | 1986-07-03 | 1996-09-10 | Advanced Magnetics, Inc. | Delivery of therapeutic agents to receptors using polysaccharides |
AUPM322393A0 (en) * | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
DK1027063T3 (da) * | 1997-09-29 | 2009-06-02 | Macfarlane Burnet Inst For Med | Mannosereceptorbærende cellelinje og antigensammensætning |
WO1999017783A1 (fr) * | 1997-10-03 | 1999-04-15 | Galenica Pharmaceuticals, Inc. | Polysaccharides formateurs d'imine, leur preparation, et leur utilisation en tant qu'adjuvants et immunostimulants |
AUPQ797700A0 (en) * | 2000-06-06 | 2000-06-29 | Austin Research Institute, The | Vaccine |
AU2001263653B2 (en) | 2000-06-06 | 2006-06-29 | Igavax Pty Ltd | Vaccine |
US20070258993A1 (en) | 2003-11-12 | 2007-11-08 | The Austin Research Institute | Dna-Carrier Conjugate |
US7968085B2 (en) * | 2004-07-05 | 2011-06-28 | Ascendis Pharma A/S | Hydrogel formulations |
DE102004049223A1 (de) * | 2004-10-08 | 2006-04-20 | Johannes-Gutenberg-Universität Mainz | Zubereitung zum Impfen, Impfverfahren und Verwendung einer Impf-Zubereitung |
EP3085373A1 (fr) * | 2006-02-22 | 2016-10-26 | 3M Innovative Properties Company | Conjugués de modificateur de réponse immunitaire |
WO2007149802A2 (fr) | 2006-06-19 | 2007-12-27 | 3M Innovative Properties Company | Formulation destinée à l'administration de modificateurs de réponse immune |
JP2009544291A (ja) | 2006-07-25 | 2009-12-17 | フォージー ヴァクシンズ ピーティーワイ エルーティーディー | ムチン1(muc1)t細胞エピトープ由来ペプチド含有癌ワクチン |
US20080149123A1 (en) | 2006-12-22 | 2008-06-26 | Mckay William D | Particulate material dispensing hairbrush with combination bristles |
US8591905B2 (en) * | 2008-10-12 | 2013-11-26 | The Brigham And Women's Hospital, Inc. | Nicotine immunonanotherapeutics |
CA2798856C (fr) | 2010-05-10 | 2019-04-23 | Ascend Biopharmaceuticals Pty Ltd | Compositions immunostimulatrices et vaccinales |
-
2012
- 2012-11-09 WO PCT/AU2012/001387 patent/WO2013067597A1/fr active Application Filing
- 2012-11-09 IN IN4251CHN2014 patent/IN2014CN04251A/en unknown
- 2012-11-09 US US14/357,520 patent/US10344261B2/en not_active Expired - Fee Related
- 2012-11-09 JP JP2014540275A patent/JP2014532799A/ja active Pending
- 2012-11-09 AU AU2012334825A patent/AU2012334825B2/en not_active Ceased
- 2012-11-09 CN CN201280065531.8A patent/CN104661683A/zh active Pending
- 2012-11-09 EP EP12847434.3A patent/EP2776070A4/fr not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
CN104661683A (zh) | 2015-05-27 |
EP2776070A4 (fr) | 2016-02-10 |
JP2014532799A (ja) | 2014-12-08 |
AU2012334825A1 (en) | 2014-06-19 |
US10344261B2 (en) | 2019-07-09 |
WO2013067597A1 (fr) | 2013-05-16 |
EP2776070A1 (fr) | 2014-09-17 |
US20150030626A1 (en) | 2015-01-29 |
AU2012334825B2 (en) | 2017-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014CN04251A (fr) | ||
MX2015003416A (es) | Metodo para mejorar las inmunoterapias especificas en el tratamiento contra el cancer. | |
ZA201500316B (en) | Novel compound with effects of thrombolysis, free radical scavenging and thrombus-targeting as well as preparation method and use thereof | |
EP2563366A4 (fr) | Utilisations de conjugués phospholipidiques d'agonistes synthétiques de tlr7 | |
MX356525B (es) | Vectores de virus asociados con adeno (aav) para uso en terapia de genes de coroideremia. | |
AU2012335543A8 (en) | HER3 antibodies and uses thereof | |
TN2012000414A1 (en) | Forms of rifaximin and uses thereof | |
GB2518813A (en) | OMV vaccine against Burkholderia infections | |
MX347734B (es) | Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas. | |
PL2707010T3 (pl) | Szczepy bakteryjne należące do rodzaju bifidobacterium do zastosowania w leczeniu hipercholesterolemii | |
MX364220B (es) | Metodos de tratamientos de fibrosis. | |
PH12015500590B1 (en) | Apixaban liquid formulations | |
MX2019001977A (es) | Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados. | |
EP3049536A4 (fr) | Procédés et compositions concernant une thérapie anticancéreuse au moyen d'agents endommageant l'adn | |
CO7160080A2 (es) | Composiciones lipídicas de racecadotrillo | |
MX2019004364A (es) | Formulaciones en gel intranasal de testosterona en dosis de menor potencia y uso de las mismas para el tratamiento de la anorgasmia o el trastorno de deseo sexual hipoactivo. | |
NZ628433A (en) | Chitosan-derived compositions | |
MX2013003859A (es) | Polimorfos de picropodofilina b o c para su uso en la terapia del cancer. | |
IN2014DN08407A (fr) | ||
IN2014DN08093A (fr) | ||
ZA201308256B (en) | Uses, methods and biological compositions of the genus paecilomyces for the control, prevention and eradication of phytoparasites in solanaceae cultures | |
PH12015501198A1 (en) | Uses of bacopa monnieri extract | |
WO2014083432A3 (fr) | Formulations intranasales de gel de testostérone à concentration inférieure pour femmes et leur utilisation pour traiter l'anorgasmie ou la baisse du désir sexuel | |
IN2014DN00168A (fr) | ||
AU2012361321A8 (en) | Pharmaceutical compositions for the treatment of tumours that express EGFR and ganglioside N-glycolyl GM3 (NEUGCGM3) |